Financial Times - Aug 18

Aug 18 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.


- Ofgem director quits in protest at changes to price cap calculation Link

- Genesis CEO exits after crypto broker took hit from Three Arrows collapse Link

- Sanofi drops experimental breast cancer drug after second trial fails Link

- Jim Ratcliffe declares interest in buying Manchester United Link


- A board member of Ofgem Christine Farnish has quit after accusing the energy regulator of prioritising companies over consumers.

- Crypto broker Genesis will cut a fifth of its staff and replace its chief executive Michael Moro as it counts the cost of lending $2.4bn to hedge fund Three Arrows Capital.

- Sanofi SA SASY.PA has abandoned development of a once-promising breast cancer drug called amcenestrant after a second failed clinical trial, dealing a blow to its pipeline of new treatments.

- Billionaire Sir Jim Ratcliffe has declared his interest in buying English football club Manchester United if its controlling owners, the Glazers, are open to a sale.

(Compiled by Bengaluru newsroom)

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.